Michael J. Kahana of the School of Arts & Sciences is featured in a front-page article for leading a $22.5 million project on restoring memory loss.
Baligh Yehia of the Perelman School of Medicine comments on studying hepatitis C treatment in the U.S.
A team of scientists and physicians at the University of Pennsylvania will lead a four-year effort worth as much as $22.5 million to develop next-generation technologies to restore memory function in people who suffer from memory loss due to disease or traumatic injury.
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
For the last century, the concept of crystals has been a mainstay of solid-state physics. Crystals are paragons of order; crystalline materials are defined by the repeating patterns their constituent atoms and molecules make.
John Wherry, PhD, an associate professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and colleagues from Massachusetts General Hospital (MGH) are co-directing a $12 million grant to study immune responses in people who have been effectively cured of hepatitis C viral infection with new, high-potency antiviral drugs.
Penn Study: Computer-Automated, Time-Lapse Embryo Photography May Increase Success of In-Vitro Fertilization
Using computer-automated, time-lapse photography of embryos in the laboratory during in-vitro fertilization may improve embryo selection, potentially increasing the chances of pregnancy among women undergoing the procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania and five other fertility centers.
Major Gaps in Hepatitis C Care Identified As New Drugs and Screening Efforts Emerge, Penn Study Finds
A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs.